(Q36323585)

13 August 2017

Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients (English)

1 reference

13 August 2017

1 reference

Françoise Kraeber-Bodéré

14

Françoise Kraeber-Bodéré

0 references

Caroline Bodet-Milin

1

Caroline Bodet-Milin

0 references

Alain Faivre-Chauvet

6

Alain Faivre-Chauvet

0 references

Ludovic Ferrer

2

Ludovic Ferrer

1 reference

13 August 2017

8

Caroline Rousseau

1 reference

13 August 2017

13

Robert M Sharkey

1 reference

13 August 2017

15

Jacques Barbet

1 reference

13 August 2017

Aurore Rauscher

3

1 reference

13 August 2017

Damien Masson

4

1 reference

13 August 2017

Latifa Rbah-Vidal

5

1 reference

13 August 2017

Evelyne Cerato

7

1 reference

13 August 2017

José Hureaux

9

1 reference

13 August 2017

Olivier Couturier

10

1 reference

13 August 2017

Pierre-Yves Salaün

11

1 reference

13 August 2017

David M Goldenberg

12

1 reference

13 August 2017

27 November 2015

1 reference

13 August 2017

Frontiers in Medicine

1 reference

13 August 2017

2

1 reference

13 August 2017

84

1 reference

Radioimmunotherapy of human tumours

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Radioimmunoconjugates for the treatment of cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

3D Slicer as a tool for interactive brain tumor segmentation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Pretargeting with the affinity enhancement system for radioimmunotherapy.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Comparison of methods for analysis of clinical [11C]raclopride studies.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4661432

Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group

22 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.3389%2FFMED.2015.00084

Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.3389%2FFMED.2015.00084

Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial

21 January 2018

1 reference

12 December 2020

Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies

1 reference

12 December 2020

Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial

1 reference

12 December 2020

Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial

1 reference

12 December 2020

A practical method for position-dependent Compton-scatter correction in single photon emission CT

1 reference

12 December 2020

Identifiers

DOI

10.3389/FMED.2015.00084

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

26640780

1 reference